Celera links up with LabCorp and Quest:
This article was originally published in Clinica
Celera Diagnostics has formed separate deals with Laboratory Corporation of America (LabCorp) and Quest Diagnostics to collaborate on tests for a number of common diseases. The agreement with LabCorp is expected to lead to tests for Alzheimer's disease, breast cancer and prostate cancer. The deal with Quest provides for the development of tests for cardiovascular disease and diabetes. The collaborations will support current and future disease association studies at Celera that seek to identify genetic markers associated with the diseases. Alameda, California-based Celera will be the preferred vendor to LabCorp and Quest for certain molecular diagnostic products.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.